Chapter 20: Drugs for Alzheimer Disease

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about a medical diagnosis, there's this expectation of precision, like engineering almost.

Right, yeah.

You break your arm and it's obvious.

Exactly.

The x -ray shows that jagged white line and the doctor just points to it and says, there it is, broken.

It's very binary.

Yeah.

And I mean, that's comforting, right?

We like things to be visible and easily categorized.

We really do.

But then you step into the world of neurodegeneration and suddenly that x -ray machine is just, it's broken.

We're looking at a diagnostic and therapeutic landscape that is, well, it's really murky.

So welcome to the deep dive.

Glad to be here.

Today, we're taking a stack of clinical sources.

Specifically, we are mastering Chapter 20 of Lynn's Pharmacotherapeutics, the section on drugs for Alzheimer's disease.

And we're extracting exactly what you need to know.

Unpacking it all.

Yeah.

For you listening, our advanced practice nursing and PA students, our mission today is to build your clinical reasoning from the ground up so you can walk into your exams in your clinic knowing how to manage this incredibly challenging condition.

And the stakes here, they're just massive.

If you look at the source data, Alzheimer's disease or AD, it affects an estimated 6 .5 million Americans.

Wow.

Yeah.

And it costs roughly $321 billion annually.

It's actually the sixth leading cause of death.

But the harshest clinical reality we have to face upfront right at the start of this chapter is this.

The neuronal damage is irreversible.

Irreversible.

Right.

AD cannot be cured.

The drugs in our current arsenal, they do very little to relieve symptoms.

They do not prevent neuronal loss.

And for a lot of patients, there isn't even a significant delay in the disease progression.

Okay.

Let's unpack this.

Because to understand how to treat Alzheimer's disease, even with those really limited tools, we first have to understand exactly what is breaking down in the brain.

Absolutely.

The physical degeneration happens in a very specific sequence.

So early in the disease, neuronal degeneration occurs in the hippocampus.

And the hippocampus, that serves as the brain's primary sorting center for short -term memories.

Right.

Exactly.

So when it starts shrinking, that explains why an inability to retain new information is typically the very first symptom we see.

Right.

The classic forgetting where the keys are or repeating questions.

Yeah.

But the disease doesn't just stop there.

It relentlessly moves outward to the cerebral cortex.

Which means the damage is expanding into the command center for speech, perception, reasoning.

It takes over everything.

Right.

So as the cortical neurons die off, the patient loses language skills.

Eventually, as that cortical degeneration becomes severe, the brain basically forgets how to regulate fundamental bodily functions.

It's devastating.

We're talking about a complete loss of speech, loss of bladder and bowel control, and a total inability for self -care.

And ultimately, it destroys enough brain function to cause death.

And parallel to that physical shrinking of the brain, we see this massive neurochemical drop.

Acetylcholine.

It's a neurotransmitter that is absolutely critical for forming memories.

In patients with advanced AD, acetylcholine levels drop by an astonishing 90 % below normal.

Hold on.

I have to push back on that for a second based on the text.

Oh, sure.

Because if acetylcholine drops by 90 % in advanced disease, but the text says cholinergic transmission is essentially normal in patients with mild AD, then a loss of acetylcholine can't be the only thing causing those early cognitive memory deficits.

What else is happening?

That is a phenomenal catch.

You're right.

Cholinergic loss alone doesn't explain the early disease.

To understand the full picture, we have to look at the structural damage happening on a microscopic level.

The plaques and tangles.

Exactly.

Two hallmark histologic changes.

Let's start outside the neuron.

We have neuritic plaques.

These are spherical bodies made of a central core of beta amyloid, which is a protein fragment, and they're surrounded by the remnants of dead neurons.

Just a graveyard of cells.

Yeah, and what's terrifying is that these plaques begin accumulating 10 to 20 years before the first symptoms ever appear.

So the damage is brewing for decades, and that's just outside the cell.

Inside the neuron, you have neurofibrillary tangles.

The text explains that in a healthy neuron, there's a protein called tau,

and it basically acts like the cross ties on a railroad track, keeping the cell's transport microtubules orderly and stable.

It holds the whole transport system together.

Yeah.

But in Alzheimer's, that tau protein becomes abnormal.

It twists into these paired helical filaments.

It forms tangles inside the cell, completely derailing that transport system.

Yeah, we can't really talk about the structural damage without mentioning the genetic link.

Specifically, apolipoprotein E or ApoE.

Oh, right, the ApoE gene.

Yeah, normally ApoE transports cholesterol, but it also plays a role in clearing out that toxic beta amyloid we just talked about.

Well, there's one specific variant, ApoE4, that is terrible at clearing amyloid.

It just leaves it there to build up.

Basically, if a patient inherits one or two copies of the gene that codes for ApoE4, their risk for AD is significantly increased.

Though it's important to note for your clinical practice, having the gene doesn't guarantee you'll get the disease, and a lot of people with AD don't have the ApoE4 gene at all.

Right, but it's a risk factor, not a crystal ball.

So we know the cellular mechanisms now, the tau tangles, the amyloid plaques, the falling acetylcholine.

How does all of this translate to the patient actually sitting in your clinic?

Who is at risk here?

Well, advancing age is obviously the major known factor.

The text notes that 90 % of patients are 65 or older.

And what else?

Other major risk factors include a family history, a history of head trauma with loss of consciousness,

and crucially, cardiovascular issues, hypertension,

atherosclerosis, dyslipidemia, diabetes.

The vascular connection is huge.

It is.

We see a strong link here because poor vascular health impairs the brain's blood flow, which in turn severely compromises the brain's ability to wash away those toxic amyloid proteins before they can form plaques.

You know, I'm glad you brought up the lifestyle factors, because we constantly hear in popular the daily crossword puzzle, eat your blueberries, stay socially active, you can sort of dementia proof your brain.

Oh, the brain games.

Right.

What does the evidence actually say about that?

It's a comforting thought, but the clinical evidence simply doesn't support it.

The 2017 systematic review by the Agency for Healthcare Research and Quality, the AHRQ, they found there is actually no good evidence supporting the association of any modifiable factor with a reduced risk for AD.

Wait, really?

None?

None.

Not diet, not exercise, not social interaction or brain games.

An unhealthy cardiovascular lifestyle can certainly accelerate the damage,

but healthy lifestyles haven't been proven to prevent the disease from taking hold in the first place.

That is deeply sobering.

And the symptom progression outlined in the text is just as relentless.

It really is.

Mild stage brings confusion, memory loss, disorientation, personality changes.

Then it advances to moderate.

This is where patients struggle with basic activities of daily living, like feeding and bathing.

You start seeing wandering, pacing, agitation.

Yeah, and sleep disturbances, including sundowning, where symptoms intensify dramatically in the evening.

Until finally reaching severe.

Total loss of speech, loss of appetite, loss of bowel and bladder control.

Complete dependence on a caregiver.

And this entire disease course can last anywhere from four to 20 years, though about eight years is typical.

So as a clinician facing this inevitable decline, how do you even approach treating it?

Because when you look at the standard clinical roadmap for Alzheimer's disease, the therapeutic goals are, well, they're incredibly modest.

What's fascinating here is just how marginal the clinical benefits actually are, even with our absolute best drugs.

The text quotes an expert who says the cognitive benefits of these medications are, quote, equivalent to losing half a pound after taking a weight loss drug for six months.

Wow.

Let that sink in.

You prescribe a medication with real side effects and the clinical difference is almost imperceptible.

Precisely.

And because of that reality, U .S.

clinical guidelines do not recommend that all patients receive drug therapy.

It must be a carefully weighed, shared decision between the provider, the patient and the family.

Let's walk the listener through how to reason through that clinical algorithm.

First, you determine the severity.

If the patient has mild or moderate AD, your first line of defense is a cholinesterase inhibitor.

Right.

But you don't just write this script and say, see you next year.

You bring them back to the clinic in two to four weeks strictly to evaluate drug tolerance.

Yes.

Tolerance first.

Then you evaluate them again in three to six months to assess efficacy.

Yeah.

Are they actually getting a benefit?

If the drug is poorly tolerated, you try switching to a different cholinesterase inhibitor.

And if the disease progresses to moderate.

And you consider adding a second drug with a completely different mechanism, Memantine.

And the absolute most crucial clinical decision point in the entire treatment algorithm is this.

You must discuss discontinuing these medications with the caregiver if benefits are no longer obtained.

Or at any point where the risks exceed the benefits, we are not treating to cure.

We are treating for quality of life.

Exactly.

And since cholinesterase inhibitors are our first line, we really need to dive into exactly how they work, their safety profiles and how you choose between them.

Let's use an analogy to visualize the mechanism of action.

Think of acetylcholine as your brain's cellular Wi -Fi signal, connecting neurons so you can form memories.

Okay.

Like that.

Acetylcholinesterase, or ACE, is like a signal jammer that clears out the old Wi -Fi signal so the next message can come through.

Cholinesterase inhibitors are drugs.

They block that jammer.

They prevent the breakdown of acetylcholine, allowing that weak Wi -Fi signal to linger a little longer in the synapse and strengthen transmission.

That perfectly illustrates the mechanism, but it also highlights the fatal flaw of these drugs.

Right.

They only work by enhancing transmission in central cholinergic neurons that are still intact.

As the disease relentlessly progresses and those neurons physically die, there's no Wi -Fi router left to broadcast the signal.

The jammer doesn't even matter anymore.

Exactly.

That's why these drugs only delay progression by a few months and provide measurable benefit in only about 1 in 12 patients.

And even with benefits that small, the side effects are very real.

Because you are elevating acetylcholine not just in the brain, but in the peripheral nervous system too, so you see classic cholinergic side effects.

The gut goes into overdrive.

Yeah.

Nausea, vomiting, dyspepsia, diarrhea.

They can also cause bronchoconstriction, meaning you have to be extremely cautious prescribing them to patients with asthma or COPD.

But the most serious safety priority you need to watch out for is cardiovascular.

Increased parasympathetic cholinergic activation in the heart can cause symptomatic bradycardia.

A slowed heart rate.

Right.

If we connect this to the bigger picture, a patient with severe Alzheimer's who develops a slow heart rate is at massive risk for fainting and falling.

A fall leading to a hip fracture in a frail dementia patient is catastrophic.

It really is.

So if your patient is experiencing bradycardia, fainting, or falls, drug withdrawal is strongly indicated.

So if they all block the same enzyme and carry these severe risks, it seems redundant to have three different drugs in this class.

I mean, why not just use Dunpeazle for everyone?

What actually separates Dunpeazle, rivastigmine, and galantamine?

Well it comes down to pharmacokinetics and side effect profiles.

Let's start with Dunpeazle.

Brand name, Aricept.

It's approved for all stages,

mild, moderate, and severe AD.

It's a reversible inhibitor, but it's highly selective for the form of AC found in the brain rather than the periphery.

Which helps mitigate some of those peripheral side effects.

And pharmacokinetically, it has a long half -life, taking about 15 days to reach steady state, so it only requires once a day oral dosing.

Then we have rivastigmine, brand name, Exelon.

This one causes irreversible inhibition of ACA, but more importantly for your elderly polypharmacy patients, it does not interact with hepatic drug metabolizing CYP450 enzymes.

Right.

No liver enzyme competition.

Yeah, it's converted into inactive metabolites by ACE itself.

And rivastigmine is available as a 24 -hour transdermal patch, which is a massive clinical advantage.

The patch keeps blood levels steady, avoiding the sharp peaks of oral dosing, which significantly minimizes those brutal GI side effects.

Oh, that makes a lot of sense.

Yeah.

And like Dunpeazle, the patch is approved for severe AD as well as mild to moderate.

Lastly, there's galantamine, brand name, Residine.

It's a reversible inhibitor approved only for mild to moderate AD.

And a unique pharmacological fact from the text, it is actually prepared by extraction from daffodil bulbs.

That's always a fun trivia fact for exams.

But for all three of these options, patient education is your best tool.

You have to start the dose low and titrate up gradually.

Because of the GI issues.

Right.

Because nausea and diarrhea can cause dangerous weight loss in the elderly,

advise the caregiver to offer nutritional supplements like boost and snacks between meals.

And always teach them to have the patient sit or stand up slowly to avoid dizziness and those devastating falls.

But as we've established, the cholinergic neurons eventually die off, rendering those inhibitors totally useless.

The brain's pathology shifts, so our therapeutic target has to shift too.

We move to a completely different neurotransmitter, glutamate, with a drug called Mementine.

Right.

Mementine.

Brand name, Nemenda.

It's a first -in -class NMDA receptor antagonist.

Because of its mechanism, it's indicated only for moderate to severe AD.

To grasp how it works, we have to understand the NMDA receptor's role in normal memory formation.

Okay.

Picture the NMDA receptor as a gateway into the neuron that lets calcium in.

Under normal, healthy conditions, magnesium sits in that gateway like a cork, tightly blocking calcium.

Okay, got the cork.

When the brain wants to form a memory, an action potential fires, releasing a massive sudden burst of glutamate.

That glutamate binds to the receptor, pops the magnesium cork out, and allows a brief, controlled influx of calcium.

And that quick burst of calcium is the crucial signal for learning.

Exactly.

The moment the signal passes, the glutamate leaves, the magnesium cork pops back in, and the channel closes.

But under pathologic conditions in Alzheimer's disease, that orderly system breaks down.

There is a slow, steady, continuous leak of glutamate.

So it's not a burst anymore, just a leak.

Right.

And because glutamate is constantly trickling into the synapse, the receptor stays activated.

The channel stays wide open.

Calcium constantly floods into the cell.

This creates a massive amount of background noise that completely overpowers the actual memory signal.

And it gets worse, right?

Yeah, because high intracellular calcium is highly toxic.

It literally causes the neurodegeneration.

Here's where it gets really interesting.

How does mementine solve this?

Well, mementine acts like a smarter, stronger cork.

It occupies the NMDA receptor channel, blocking that slow, low -level pathologic calcium leak.

It solaces the background noise.

Exactly, and allows the cell to normalize.

But when a true action potential fires and a massive burst of glutamate arrives to form a memory, that high level of glutamate is strong enough to temporarily knock mementine out of the way.

Oh, wow.

Yeah, the true memory signal gets through, and then mementine immediately re -blocks the channel.

It's an incredibly elegant mechanism of action.

And clinically, mementine is generally well tolerated.

Dizziness, headache, and confusion are the main side effects, occurring in only 5 to 7 % of patients.

But as a prescriber, you must be hyper -vigilant about one critical drug interaction.

Oh, the urine issue.

Yes.

Drugs that alkalinize the urine, such as sodium bicarbonate, they drastically decrease the renal excretion of mementine.

Because of ion trapping in the kidneys, right?

The alkaline urine causes the mementine to be reabsorbed back into the bloodstream rather than excreted, which leads to toxic accumulation in the blood.

Exactly.

So, cholinesterase inhibitors in mementine treat the symptoms.

But what about treating the underlying disease?

What about clearing out those toxic beta amyloid plaques we talked about at the beginning?

That brings us to the newest, most controversial class of drugs, the monoclonal antibodies.

This is where clinical science meets regulatory drama.

In 2021, the FDA approved Aducanumab, brand name Aduhome, via an accelerated approval pathway.

It was the first new AD drug in nearly two decades.

But the controversy was intense.

Very.

The FDA's own scientific advisory panel strongly recommended against approval because the Phase III clinical trials yielded totally contradictory findings on whether it actually worked.

Following the FDA's decision to approve it anyway, three members of the FDA committee actually resigned in protest.

Wait, three FDA members resigned?

Yeah, they actually resigned.

The justification for approval was based on what we call surrogate endpoints.

Because it's a monoclonal antibody, it crosses the blood -brain barrier and binds directly to beta amyloid, stimulating the immune system to clear the plaques.

And the MRIs proved it worked.

Unequivocally.

The MRIs proved it was highly successful at removing those plaques.

But removing the plaques has not yet proven to equate to a definitive clinical improvement in the patient's cognitive decline.

This puts you, the clinician, in an incredibly difficult position.

You have a desperate family sitting across from you asking for this $30 ,000 a year miracle drug.

But you have to balance that against severe life -threatening risks.

Because both Aducanumab and the newer drug approved in 2023, Lacanumab, carry a black box warning for ARIA.

This raises an important question about risk versus reward.

ARIA stands for amyloid -related imaging abnormalities.

It presents on MRIs as localized cerebral edema, brain swelling,

and micro hemorrhages, brain bleeding.

While often asymptomatic, ARIA can be fatal.

And crucially, patients who carry that ApoE4 gene, they are at a dramatically higher risk for developing these brain bleeds.

Because of this, the clinical monitoring required is just intense.

First, it is only approved for patients in the mild stage of AD.

Before starting, they need a baseline MRI.

Then they require follow -up MRIs prior to infusions at weeks 5, 7, 9, and 12 just to monitor for bleeding and swelling.

A huge commitment.

Yeah.

And you also have to carefully screen patients.

Because if they have uncontrolled hypertension or are on anticoagulants, the risk of a fatal brain bleed might just be too high to justify an uncertain cognitive benefit.

It is a staggering burden on the patient and the health care system.

And unfortunately, cognitive decline is only one aspect of severe AD.

As a prescriber, you also have to address the behavioral reality.

Over 80 % of Alzheimer's patients eventually develop neuropsychiatric symptoms.

Agitation, aggression, delusions, hallucinations.

Yes.

And your pharmacological toolbox here is practically empty.

It is extremely limited.

Most drug classes fail to provide meaningful release.

The text notes that there is convincing evidence for only two second -generation antipsychotics, risperidone, and alanzapine.

And they just offer modest benefits, right?

Modest benefits in reducing these psychiatric symptoms.

However, they come with a grim black box warning of their own.

They slightly increase mortality in elderly patients with dementia -related psychosis, mostly from sudden cardiovascular events and infections.

What about other psych meds?

Conventional antipsychotics, mood stabilizers, antidepressants, they show little to no evidence of benefit whatsoever.

It's a brutal clinical reality.

You are constantly balancing marginal benefits against very real, dangerous side effects, whether it's bradycardia, brain bleeds, or increased mortality.

Which brings us back to the core mystery of Alzheimer's disease.

The monoclonal antibody saga forces us to confront something fundamental.

We develop drugs that successfully do exactly what we wanted them to do.

They clear the beta amyloid plaques from the brain, but the patients aren't definitively getting better.

The text actually points this out explicitly.

The apparent lack of clinical improvement, despite successfully clearing the plaques, is forcing the entire scientific community to re -examine the core amyloid hypothesis.

Right.

I mean, think about it.

If removing the plaque doesn't cure the disease, is it possible that amyloid plaque isn't the driver of Alzheimer's at all?

What if the plaques are just a symptom, just a tombstone marking where the damage has already been done?

If that's true, where does neuropharmacology go next?

That is the frontier you will be practicing in.

It requires immense critical thinking and a willingness to question our most basic clinical assumptions.

So what does this all mean?

It means your clinical reasoning is more important than ever.

You can't just memorize an algorithm.

You have to understand the path of physiology behind it, weigh the risks of every single prescription, and keep the patient's actual quality of life at the center of every single decision.

To you, our listener, thank you for joining us on this deep dive.

From the entire Last Minute Lecture Team, we wish you the absolute best of luck on your exams and in your future practice.

Keep questioning, keep learning, and we'll see you next time.